Showing 8181-8190 of 9548 results for "".
- Doctors Welcome VOLBELLA XC for Lipshttps://practicaldermatology.com/news/doctors-welcome-volbella-xc-for-lips/2458401/Allergan’s JUVÉDERM VOLBELLA XC is here. The newly approved filler is now available for lip augmentation and correction of perioral rhytids in adults over the age of 21. Physicians can purchase VOLBELLA XC after completion of an
- New from NeoStrata: Introducing the ProSystem Retinol Peelhttps://practicaldermatology.com/news/new-from-neostrata-the-prosystem-retinol-peel/2458398/NeoStrata is rolling out the NeoStrata ProSystem Retinol Peel, the first retinol peel for the brand. The peel contains 3% Retinol plus Retinol Boosting Complex to exfoliate and improve the appearance of fine lines and wrinkles, help reduce acne,
- Opdivo Stabilized Patient-reported Outcomes in Previously Treated Recurrent or Metastatic SCC of Head and Neckhttps://practicaldermatology.com/news/opdivo-stabilized-patient-reported-outcomes-in-previously-treated-recurrent-or-metastatic-scc-of-head-and-neck/2458409/Bristol-Myers Squibb Company reported new patient-reported quality-of-life data from an exploratory endpoint in the pivotal Phase 3 CheckMate -141 trial evaluating Opdivo in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after platinum therapy compared to inves
- Phase 3 Study: Yervoy Improves Overall Survival in Fully Resected Stage III Melanoma Patientshttps://practicaldermatology.com/news/phase-3-study-yervoy-improves-overall-survival-in-fully-resected-stage-iii-melanoma-patients/2458408/Yervoy 10 mg/kg demonstrated superiority versus placebo on all survival endpoints in the Phase 3 trial CA184-029 (EORTC 18071) evaluating stage III melanoma patients who are at high risk of recurrence following complete surgical resection, according to Bristol-Myers Squibb Company. In the study,
- New From Neocutis: Meet the Micro-Riche Linehttps://practicaldermatology.com/news/new-from-neocutis-meet-the-micro-riche-line/2458420/NEOCUTIS is rolling out a new line. The MICRO-RICHE ultra-hydrating line will expand the company’s MICRO-PROTEIN Complex (MPC) product line. The new MICRO-RICHE line includes more emollient versions of MICRO-NIGHT and MICRO-EYE to keep skin nourished and hydrated as winter approache
- Beauty Business to Go Green with New Master Class, Institutehttps://practicaldermatology.com/news/beauty-business-to-go-green-with-new-master-class-institute/2458421/The newly formed National Beauty Science Institute (NBSI) aims to promote sustainability, authenticity and green energy in the beauty business. The group will hold its first Master Class in April 2017 to educate students and consumers on the science and sustainability of beauty – a
- Launches, Anniversaries and More: Aesthetic News from Around the Webhttps://practicaldermatology.com/news/launches-anniversaries-and-more-aesthetic-news-from-around-the-web/2458425/RealSelf Rolls Out RealSelf Business Pages RealSelf is launching of RealSelf Business Pages so doctors can showcase the full range of providers at a practice as well as the tr
- Cynosure to Name Stephen J. Webber as New CFOhttps://practicaldermatology.com/news/cynosure-to-name-stephen-j-webber-as-new-cfo/2458436/Cynosure, Inc. announced that Stephen J. Webber will join the company on October 10, 2016 as Executive Vice President. Mr. Webber will then become Chief Financial Officer and Chief Accounting Officer effective upon the filing in Novembe
- Is Bigger Better? Group Practices Become the New Normhttps://practicaldermatology.com/news/group-practices-are-the-new-norm/2458438/Group physician practices are the new normal, and it seems that dermatologists were ahead of the consolidation curve, according to research in the September 2016 issue of Health Affairs. Researchers examined physician consolidation for both primary care provide
- Orphan Drug Designation Granted to Nintedanib for Systemic Sclerosishttps://practicaldermatology.com/news/orphan-drug-designation-granted-to-nintedanib-for-systemic-sclerosis/2458441/The European Commission (EC) and the FDA have granted Orphan Drug Designation to Boehringer Ingelheim's nintedanib for the treatment of systemic sclerosis (SSc, also known as scleroderma), including the associated interstitial lung disease (SSc-ILD).